Revenue
2022
2023
2024
2025
Zentalis Pharmaceuticals, Inc. (ZNTL)
Price$3.99Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — | — | — |
| Research & development | $107.3M | $167.8M | $189.6M | $172.7M | $175.6M | $84.9M | $38.4M |
| Operating expenses | $152.8M | $258.6M | $299.5M | $227.3M | $216.5M | $118.8M | $46.8M |
| Operating income | −$152.8M | −$191.2M | −$299.5M | −$227.3M | −$216.5M | −$118.8M | −$46.8M |
| Operating margin | — | −283.57% | — | — | — | — | — |
| EBITDA | −$152.1M | −$189.9M | −$298.1M | −$225.9M | −$216.0M | −$118.6M | −$46.7M |
| EBITDA margin | — | −281.65% | — | — | — | — | — |
| Net income | −$137.1M | −$165.8M | −$292.2M | −$236.8M | −$158.7M | −$117.8M | −$45.7M |
| Net profit margin | — | −245.96% | — | — | — | — | — |
| Basic EPSper basic share | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | — |
| Diluted EPSper diluted share | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | -$8.16 |
Owners
Reported shareholders
≈18.85%of listed shares
WALTERS WILLIAM THURMAN / WALTERS GROUP / WALTERS SUSAN BERKLEY13.51M shares · Dec 31, 2025
View holders
| Holder | % owned |
|---|---|
WALTERS WILLIAM THURMAN / WALTERS GROUP / WALTERS SUSAN BERKLEY | ≈18.85%13.51M shares |
GOEL DAVID E. / Matrix Capital Management Company, LP | ≈9.01%6.46M shares |
5AM Venture Management, LLC | 5.51%3.95M shares |
BlackRock, Inc. | 5.24%3.75M shares |
Squadron Capital Management LLC | 5.16%3.7M shares |
TWO SIGMA INVESTMENTS, LP | 4.22%3.02M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.96%2.84M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.74%2.68M shares |
CITADEL ADVISORS LLC | 3.21%2.3M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.25%1.61M shares |
Opaleye Management Inc. | 1.97%1.41M shares |
ORBIMED ADVISORS LLC | 1.94%1.39M shares |
Decheng Capital LLC | 1.85%1.32M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.79%1.28M shares |
BANK OF AMERICA CORP /DE/ | 1.56%1.11M shares |
Paul Andrea | ≈1.49%1.07M shares |
Ishara Investments LP | 1.43%1.03M shares |
PRIMECAP MANAGEMENT CO/CA/ | 1.34%957.42K shares |
Pfizer Inc | 1.33%953.83K shares |
Soleus Capital Management, L.P. | 1.33%950K shares |
Percentages use 71.67M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 10, 2026Form 4 · 10b5-1 | Vultaggio VincentPAO and PFO | SellCommon Stock | 6.9K | $2.42 | $16.7K | 146.5K |
| Feb 9, 2026Form 4 · 10b5-1 | Vultaggio VincentPAO and PFO | SellCommon Stock | 3.4K | $2.39 | $8.1K | 153.4K |
| Feb 9, 2026Form 4 | Bruns IngmarChief Medical Officer | SellCommon Stock | 335 | $2.39 | $800.65 | 33.3K |
| Feb 9, 2026Form 4 | EASTLAND JULIA MARIECEO & President | SellCommon Stock | 889 | $2.39 | $2.1K | 79.1K |
| Feb 6, 2026Form 4 · 10b5-1 | Vultaggio VincentPAO and PFO | SellCommon Stock | 30.0K | $2.43 | $72.8K | 156.8K |